Sector consensus Charles River Laboratories International, Inc.

Equities

Real-time Estimate Cboe BZX Other stock markets 15:36:18 07/02/2025 GMT			5-day change	1st Jan Change
165.28 ^USD	-0.59%		+0.60%	-10.21%

02-05	Morgan Stanley Adjusts Charles River Laboratories International's Price Target to $184 From $220	MT
01-23	Goldman Sachs Adjusts Charles River Laboratories International Price Target to $190 From $220, Maintains Buy Rating	MT

Sector:

Location:

X axis:

Main competitors

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Average Target P.	Ecart obj. / dr	Nbr of analysts
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	US$193.34	+16.28%	18
LONZA GROUP AG	CHF 657.95	+7.33%	21
IQVIA HOLDINGS INC.	US$248.08	+18.16%	23
CELLTRION, INC.	₩236,564.63	+30.7%	21
ICON PUBLIC LIMITED COMPANY	US$258.12	+31.73%	17
UNITED THERAPEUTICS CORPORATION	US$401.08	+13.38%	13
MODERNA, INC.	US$62.32	+85.43%	22
BIO-TECHNE CORPORATION	US$86.8	+15.72%	13
MEDPACE HOLDINGS, INC.	US$343.83	-4.75%	10
TEMPUS AI, INC.	US$58.6	-9.83%	10
QIAGEN N.V.	US$51.24	+20.73%	17
REVOLUTION MEDICINES, INC.	US$73.29	+68.2%	14
BLUEPRINT MEDICINES CORPORATION	US$126.05	+14.99%	19
TELIX PHARMACEUTICALS LIMITED	A$25.76	-11.58%	7
PHARMARON BEIJING CO., LTD.	CN¥28.9	+11.2%	11
HANGZHOU TIGERMED CONSULTING CO., LTD	CN¥60.66	+20.64%	17
IONIS PHARMACEUTICALS, INC.	US$61.32	+87.92%	25
ALKERMES PLC	US$34.38	+9.54%	13
TG THERAPEUTICS, INC.	US$40.33	+20.4%	6
Average	12,598.77	+23.48%	16
Weighted average by Cap.	24,687.12	+21.08%	18